SCHEMBL1554847

SCHEMBL1554847

CC(C)(C)OC(=O)CCN(CCO)c1ccc(OC(F)(F)F)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.39
KMT2A Q03164 2/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
ATM Q13315 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SCN9A Q15858 5/20 0.36
KMO O15229 2/20 0.35
GAA P10253 1/20 0.34
PKM P14618 1/20 0.34
HTT P42858 1/20 0.34
MCL1 Q07820 1/20 0.34
GSTO1 P78417 1/20 0.33
GRIN2B Q13224 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1555167 0.87 APP (0.40) APPSCN9AKMOGSTO1GRIN2B
SCHEMBL1555550 0.87 RAB9A (0.38) APPMAPTSCN9AKMOGSTO1
SCHEMBL735140 0.86 KMT2A (0.41) KMT2AMAPTMEN1LMNATP53
SCHEMBL1555656 0.84 KMT2A (0.38) KMT2AMAPTMEN1LMNATP53
SCHEMBL1555386 0.83 MAPT (0.38) APPMAPTSCN9AGSTO1PPARD
SCHEMBL16333309 0.75 RAB9A (0.40) MAPTSCN9AKMOFFAR1FFAR4
SCHEMBL27877240 0.74 SCN3A (0.39) APPSCN9APPARGPPARDPPARA
SCHEMBL1556312 0.74 S1PR2 (0.43) APPMAPTSMN1; SMN2GAAGSTO1
SCHEMBL734811 0.72 RAB9A (0.42) MAPTLMNASMN1; SMN2
SCHEMBL734806 0.72 CETP (0.37) MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2491022-B1 DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2014-12-31 EP disclosed
US-8445674-B2 Heterocyclyl compounds Hoffmann-La Roche Inc (US) 2013-05-21 US disclosed
CN-102762541-A Diaza derivatives as modulators of chemokine receptors HOFFMANN LA ROCHE 2012-10-31 CN disclosed
EP-2491022-A1 DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2012-08-29 EP disclosed
WO-2011048032-A1 DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-28 WO disclosed
US-20110092698-A1 NOVEL HETEROCYCLYL COMPOUNDS F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092698-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR1 APP 2929/4885KMT2A 4583/4885MAPT 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.